Consistent with these data, the HER2-enriched (HER2-E) intrinsic breast cancer subtype has been associated with better responses [18–21] and favorable long-term outcomes in patients treated with neoadjuvant HER2-targeted therapy [18, 21, 22]. The gene discussed is ERBB2; the disease is breast carcinoma.